Patents Assigned to Merck Patent GmbH
  • Peroxynitrite rearrangement catalysts
    Publication number: 20040127479
    Abstract: The invention relates to the use of paramagnetic 3-, 8-substituted porphyrin derivatives with various substituents in 13- and 17-positions of the porphyrin skeleton as peroxynitrite rearrangement catalysts.
    Type: Application
    Filed: August 27, 2003
    Publication date: July 1, 2004
    Applicant: Merck Patent GmbH
    Inventors: Gisbert Depke, Margrit Hillmann, Guenter Michl, Johannes Platzek, Detlev Suelzle, Roland Neuhaus
  • Vapor-deposition material for the production of high-refractive-index optical layers, and process for the production of the vapor-deposition material
    Patent number: 6756137
    Abstract: A vapor-deposition material for the production of high-refractive-index optical layers of titanium oxide, titanium and lanthanum oxide under reduced pressure comprising a sintered mixture having the composition TiOx+z*La2O3, where x=1.5 to 1.8 and z=10 to 65% by weight, based on the total weight of the mixture. The constituents of the mixture are in the range of 10 to 65% by weight of lanthanum oxide, 38 to 74% by weight of titanium oxide and 2 to 7% by weight of titanium.
    Type: Grant
    Filed: December 28, 2001
    Date of Patent: June 29, 2004
    Assignee: Merck Patent GmbH
    Inventors: Uwe Anthes, Martin Friz
  • Piperidine alcohols
    Patent number: 6756370
    Abstract: The invention relates to compounds of formula (I), wherein R1, R2 and A have the meanings given in claim 1, are potent 5-HT2A antagonists and are suitable for treating psychoses, schizophrenia, depression, neurological disorders, impaired memory, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, eating disorders such as bulimia and anorexia nervosa, Pre-Menstrual Syndrome and/or for positively influencing obsessive-compulsive disorders, (OCD).
    Type: Grant
    Filed: February 21, 2002
    Date of Patent: June 29, 2004
    Assignee: Merck Patent GmbH
    Inventors: Helmut Prücher, Henning Böttcher, Karl-August Ackermann, Rudolf Gottschlich, Christoph van Amsterdam, Christoph Seyfried, Jürgen Harting, Gerd Bartoszyk, Hartmut Greiner
  • TN and STN liquid-crystal displays
    Patent number: 6753045
    Abstract: The invention relates to TN and STN liquid-crystal displays and to the novel nematic liquid-crystal mixtures used therein, characterized in that they comprise one or more compounds of the formula I and at least one compound of the formula II and at least one compound of the formula III in which R1, R2, R3, R4, L1, L2 and X are as defined in claim 1.
    Type: Grant
    Filed: June 27, 2002
    Date of Patent: June 22, 2004
    Assignee: Merck Patent GmbH
    Inventor: Juliane Suermann
  • Liquid crystalline compound, medium and display
    Patent number: 6753046
    Abstract: The invention relates to a liquid crystalline compound of the formula I wherein X1 and R1 are defined as in claim 1. The invention further relates to a liquid crystalline medium based on a mixture of polar compounds of positive dielectric anisotropy containing one or more compounds of formula I and its use in electrooptical displays and projection systems, in particular reflective displays and displays based on a birefringence effect, such as OCB displays.
    Type: Grant
    Filed: November 7, 2002
    Date of Patent: June 22, 2004
    Assignee: Merck Patent GmbH
    Inventors: Atsutaka Manabe, Matthias Bremer
  • Calcium phosphate cement composition and a method for the preparation thereof
    Publication number: 20040112256
    Abstract: The invention describes a new calcium phosphate cement powder, whose composition can best be described over the Ca/P molar ratio range of 1.35 to 1.40, most preferably 1.39, and whose two components were prepared by wet chemical synthesis procedures. One component is chemically-synthesized, bi-phasic alpha-TCP (Ca3(PO4)2, 95 wt %)+HA (Ca10(PO4)6(OH)2, 5 wt %) powder, while the second component is again a chemically-synthesized, single-phase DCPD (CaHPO4.2H20) powder. A setting solution (Na2HPO4.2H2O) is used to form a self-setting calcium phosphate cement from the powder mixture. This cement can be used as bone filler or bone substitute in applications, which require higher rates of resorption.
    Type: Application
    Filed: August 26, 2003
    Publication date: June 17, 2004
    Applicant: Merck Patent GmbH
    Inventor: Ahmet Cuneyt Tas
  • Multilayer pearl lustre pigment
    Patent number: 6747073
    Abstract: Multilayer pearl luster pigment on the basis of a platelet-shaped substrate comprising a material having a refractive index of more than 1.8, which comprises at least (i) a first layer of a material of low refractive index in the range from 1.35 to 1.8, (ii) optionally, a second layer of a material having a refractive index of more than 1.8. (iii) a semitransparent metal layer which is applied to the substrate or to the layers (i) or (ii) and (iv) if desired, an aftercoating, the substrate being platelet-shaped titanium dioxide, zirconium dioxide, &agr;-iron(III) oxide, tin dioxide or zinc oxide.
    Type: Grant
    Filed: July 18, 2001
    Date of Patent: June 8, 2004
    Assignee: Merck Patent GmbH
    Inventors: Gerhrad Pfaff, Stephanie Andes, Gerald Fuchs-Pohl
  • Pigment mixture comprising BiOCI pigments
    Patent number: 6743285
    Abstract: The present invention relates to pigment mixtures in the form of a dispersion or powder, consisting of at least two components, where component A comprises coated or uncoated BiOCl pigments in the form of a powder or dispersion, and component B comprises pearlescent pigments, platelet-shaped, needle-shaped or spherical colorants and/or fillers, and to the use thereof in paints, coatings, printing inks, plastics, powder coatings, plastic films, for the finishing of seed and in particular in cosmetic formulations.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: June 1, 2004
    Assignee: Merck Patent GmbH
    Inventors: Ralf Anselmann, Uta Hillgärtner, Sabine Schoen
  • Indol-3-yl derivatives
    Patent number: 6743810
    Abstract: Indol-3-yl derivatives of the general formula I in which A, B, X, R1, R2, R3, R4, R5, n and m are as defined in patent claim 1, and their physiologically acceptable salts or solvates are integrin inhibitors and can be employed for combating thromboses, cardiac infarction, coronary heart diseases, arteriosclerosis, inflammations, tumours, osteoporosis, rheumatic arthritis, macular degenerative disease, diabetic retinopathy, infections and restenosis after angioplasty or in pathological processes maintained or propagated by angiogenesis.
    Type: Grant
    Filed: August 9, 2002
    Date of Patent: June 1, 2004
    Assignee: Merck Patent GmbH
    Inventors: Matthias Wiesner, Simon Goodman, Rudolf Gottschlich
  • In-line application of UV varnish
    Publication number: 20040101671
    Abstract: The present invention relates to a print product in which a layer of offset printing ink, a primer layer applied over the entire surface or over part of the surface and, as uppermost layer, a layer of UV-curable varnish applied over the entire surface or over part of the surface are located on a substrate, characterised in that the primer layer comprises platelet-shaped particles. The invention furthermore relates to a process for the production of the print product and to the use thereof as outer packaging or secondary packaging in the foods and cosmetics area.
    Type: Application
    Filed: August 19, 2003
    Publication date: May 27, 2004
    Applicant: Merck Patent GmbH
    Inventor: Thomas Rathschlag
  • Liquid-crystalline medium
    Patent number: 6740369
    Abstract: Liquid-crystalline mediums based on a mixture of polar compounds of negative dielectric anisotropy, comprising one or more compounds of the general formula I, in which R11 is an alkyl group having from 1 to 12 carbon atoms or an alkenyl group having from 2 to 12 carbon atoms, and R12 is an alkenyl group having from 2 to 12 carbon atoms, are useful for electro-optical display elements such as active matrix addressed displays which operate on the ECB and/or VA principles.
    Type: Grant
    Filed: July 30, 2002
    Date of Patent: May 25, 2004
    Assignee: Merck Patent GmbH
    Inventors: Melanie Klasen-Memmer, Malgorzata Rillich, Volker Reiffenrath
  • Method for producing high-purity sulphuric acid
    Patent number: 6740302
    Abstract: The invention relates to a novel method for producing high-purity sulfuric acid for use in the semiconductor industry. The method comprises the addition of a hydrogen peroxide solution to an engineered oelum in order to reduce the SO2 concentration, evaporation of the SO3 and separation of acid traces. The high-purity SO3 is then enriched with inert gas and the SO3 is absorbed into sulfuric acid.
    Type: Grant
    Filed: June 26, 2002
    Date of Patent: May 25, 2004
    Assignee: Merck Patent GmbH
    Inventors: Martin Hostalek, Werner Büttner, Rolf Hafner, Chih-Peng Lu, Ching-Jung Kan, Ekkehart Seitz, Ernst Friedel
  • Pyrrole derivatives as phosphodiesterase VII inhibitors
    Patent number: 6737436
    Abstract: Compounds of the formula I in which R1 and R2, independently of one another, each denote H, A, OA, SA or HaI, R3 denotes H or A, R4 denotes A or NH2, R5 denotes H, NH2, NHA or NA2, A denotes alkyl having 1 to 10 carbon atoms, alkenyl, cycloalkyl or alkylenecycloalkyl, Hal denotes F, Cl, Br or I, and their physiologically acceptable salts and/or solvates, as phosphodiesterase VII inhibitors.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: May 18, 2004
    Assignee: Merck Patent GmbH
    Inventors: Hans-Michael Eggenweiler, Rochus Jonas, Michael Wolf, Michael Gassen, Thomas Welge
  • Sulfonyloxazoleamines
    Patent number: 6737426
    Abstract: The invention relates to compounds of the general formula (I) where R1 and R2 independently of one another are H, —R6, C3-C8-cycloalkyl, —(CH2)n—R7, —(CH2)n—O—R6, —(CH2)n—NH2, —(CH2)n—NHR6, —(CH2)—N(R6)2, C2-C6-alkenyl or, where appropriate, together form a mononuclear saturated heterocycle having one or two nitrogen, oxygen and/or sulfur atoms, R3 and R4 independently of one another are H, —R6, —CF3, —NO2, —Hal, —OH, —O—R6, —NH2, —NH—R6 or —N(R6)2, R5 is a 5- or 6-membered, saturated or unsaturated heterocycle having one or two nitrogen, oxygen and/or sulfur atoms which may be mono- or disubstituted by R6, —CF3, —NO2, —Hal, —OH, —O—R6, —NH2, —NH—R6 or —N(R6)2, and R6 is C1-C6-alkyl, R7 is R3- and/or R4-substituted phenyl, n is 0 to 2, and physiologically acceptable salts or solvates thereo
    Type: Grant
    Filed: May 28, 2002
    Date of Patent: May 18, 2004
    Assignee: Merck Patent GmbH
    Inventors: Rolf Gericke, Henning Böttcher, Michael Gassen, Hartmut Greiner
  • Liquid-crystalline medium and liquid-crystal display having high twist
    Publication number: 20040089843
    Abstract: The present invention relates to a liquid-crystalline medium having high twist, to the use thereof for electro-optical purposes, and to displays containing this medium.
    Type: Application
    Filed: August 4, 2003
    Publication date: May 13, 2004
    Applicant: Merck Patent GmbH
    Inventors: Juliane Suermann, Meike Krumwiede
  • Light-protection agents
    Publication number: 20040091433
    Abstract: The invention relates to a preparation having light-protection properties comprising at least one compound of the formula I 1
    Type: Application
    Filed: July 18, 2003
    Publication date: May 13, 2004
    Applicant: Merck Patent GmbH
    Inventors: Herwig Buchholz, Christophe Carola, Sophie Perruchon
  • Method and device for the continuous production of NaAlCl4 or NaFeCl4
    Patent number: 6733738
    Abstract: The invention relates to a method and a device for the production of NADCl4 in which D is aluminium or iron, where, in a first reaction step, a melt of aluminium or iron is reacted with chlorine gas to give gaseous metal halide, and this is subsequently reacted, in a second reaction step, with solid sodium chloride to give the corresponding compound and is separated off as a melt.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: May 11, 2004
    Assignee: Merck Patent GmbH
    Inventor: Hans Leonhard Ohrem
  • Method of preparing porous calcium phosphate morsels and granules via gelatin processing
    Publication number: 20040076685
    Abstract: The invention describes a method of preparing alpha- or beta-tricalcium phosphate, brushite (CaHPO4.2H2O), calcium pyrophosphate (Ca2P2O7) or hydroxyapatite (Ca5(PO4)3(OH)) or mixtures thereof in the form of morsels or granules via gelatin processing. These morsels or granules can be used as bone or tooth fillers or bone substitutes in applications, especially when higher rates of resorption or taking part in the bone remodelling processes of the implanted material are desired.
    Type: Application
    Filed: July 11, 2003
    Publication date: April 22, 2004
    Applicant: Merck Patent GmbH
    Inventor: Ahmet Cuneyt Tas
  • Chiral compounds
    Patent number: 6723395
    Abstract: The invention relates to chiral compounds of formula I, to liquid crystal mixtures comprising at least one chiral compound of formula I, to chiral linear or crosslinked liquid crystal polymers obtainable by polymerizing a polymerizable mixture comprising at least one chiral compound of formula I, to the use of chiral compound of formula I and mixtures and polymers obtained thereof in liquid crystal displays, active and passive optical elements, adhesives, synthetic resins with anisotropic mechanical properties, cosmetic and pharmaceutical compositions, diagnostics, liquid crystal pigments, for decorative and security applications, nonlinear optics, optical information storage or as chiral dopants, and to a liquid crystal display comprising a mixture comprising at least one chiral compound of formula I.
    Type: Grant
    Filed: July 1, 2002
    Date of Patent: April 20, 2004
    Assignee: Merck Patent GmbH
    Inventors: Alison Linda May, Simon Greenfield, Mark John Goulding, Owain Llyr Parri
  • Indole derivatives
    Patent number: 6723725
    Abstract: Indole derivatives of formula I, their salts and solvates, have valuable pharmacological properties together with good tolerability, as they have actions on the central nervous system: wherein R1 and R3 are as defined herein. The compounds have a strong affinity for 5-HT2A receptors, and furthermore exhibit 5HT2A receptor-antagonistic properties. These are therefore suitable both in veterinary and in human medicine for the treatment of functional disorders of the central nervous system and also of inflammation.
    Type: Grant
    Filed: January 22, 2002
    Date of Patent: April 20, 2004
    Assignee: Merck Patent GmbH
    Inventors: Henning Böttcher, Joachim März, Hartmut Greiner, Jürgen Harting, Gerd Bartoszyk, Christoph Seyfried, Christoph van Amsterdam